PMC-122

N/A

Report date: 2022/02/23 17:47:24

Base Information

Drug NamePMC-122

Drug Alias NamePMC-122

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionCluster of differentiation 47 inhibitorsProgrammed death-ligand 1 blockers

TargetsProgrammed death-ligand 1Cluster of differentiation 47

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesPharmabcine

China Registration ClassN/A

Develop Information

Active CompaniesPharmabcine

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A